首页> 美国卫生研究院文献>BMJ Case Reports >Case Report: Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta
【2h】

Case Report: Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta

机译:病例报告:难治性PMR合并主动脉炎:使用抗IL6单克隆抗体(tocilizumab)进行挽救生命的治疗以及升主动脉的手术重建

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aortitis is uncommon but well described in patients with polymyalgia rheumatica (PMR). While glucocorticoid remains the mainstay therapy for large-vessel vasculitis, there have been cases where tocilizumab therapy led to clinical and serological improvement in patients with relapsing or refractory disease. We report a case of life-threatening PMR with aortitis in the absence of manifestations related to giant cell arteritis, which, having failed to respond to corticosteroid therapy, was successfully treated with tocilizumab and emergency reconstruction of the ascending aorta. This case adds to the literature supporting the potential value of interleukin-6 inhibition in rare rheumatological conditions such as inflammatory aortitis.
机译:风湿性多肌痛(PMR)患者不常见主动脉炎,但已有很好的描述。尽管糖皮质激素仍然是大血管血管炎的主要治疗方法,但在某些情况下,托珠单抗治疗可导致复发或难治性疾病患者的临床和血清学改善。我们报告了一例存在主动脉炎的危及生命的PMR病例,没有与巨细胞性动脉炎相关的表现,对皮质类固醇疗法没有反应,已成功用tocilizumab治疗并紧急重建升主动脉。这种情况增加了支持白细胞介素6抑制在罕见的风湿病如炎症性主动脉炎中的潜在价值的文献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号